Do analysts rate QLGN or AMOD?

Alpha Modus has a consensus price target of $60.00, suggesting a potential upside of 1,487.30%. Given Alpha Modus' stronger consensus rating and higher probable upside, analysts plainly believe Alpha Modus is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alpha Modus 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is QLGN or AMOD more profitable?

Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A N/A -202.16% Alpha Modus N/A N/A -610.34%

Do analysts rate DTSS or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Datasea 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DTSS or QLGN more profitable?

Company Net Margins Return on Equity Return on Assets Datasea N/A N/A N/A Qualigen Therapeutics N/A N/A -202.16%

Do analysts recommend NVNI or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nvni Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NVNI or QLGN more profitable?

Company Net Margins Return on Equity Return on Assets Nvni Group N/A N/A N/A Qualigen Therapeutics N/A N/A -202.16%

Do analysts recommend QLGN or NXTT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Next Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SEAC or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SeaChange International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, SEAC or QLGN?

Qualigen Therapeutics has lower revenue, but higher earnings than SeaChange International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SeaChange International $32.76M 0.25 -$11.40M N/A N/A Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A

Is SEAC or QLGN more profitable?

Company Net Margins Return on Equity Return on Assets SeaChange International N/A N/A N/A Qualigen Therapeutics N/A N/A -202.16%

Qualigen Therapeutics (QLGN) Competitors

$1.23 +0.01 (+0.82%)

As of 10/2/2026

Compare

QLGN vs. AMOD, DTSS, NVNI, NXTT, and SEAC

Should you buy Qualigen Therapeutics stock or one of its competitors? Qualigen Therapeutics's main competitors and comparable companies include Alpha Modus (AMOD), Datasea (DTSS), Nvni Group (NVNI), Next Technology (NXTT), and SeaChange International (SEAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Qualigen Therapeutics compare to Alpha Modus?

Qualigen Therapeutics (NASDAQ:QLGN) and Alpha Modus (NASDAQ:AMOD) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Qualigen Therapeutics has higher earnings, but lower revenue than Alpha Modus. Alpha Modus is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Alpha Modus	$10K	1,886.22	-$8.02M	-$8.22	N/A

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 15.9% of Alpha Modus shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 78.2% of Alpha Modus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Alpha Modus had 13 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 13 mentions for Alpha Modus and 0 mentions for Qualigen Therapeutics. Alpha Modus' average media sentiment score of 0.34 beat Qualigen Therapeutics' score of 0.00 indicating that Alpha Modus is being referred to more favorably in the news media.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Alpha Modus	Neutral

Alpha Modus has a consensus price target of $60.00, suggesting a potential upside of 1,487.30%. Given Alpha Modus' stronger consensus rating and higher probable upside, analysts plainly believe Alpha Modus is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alpha Modus	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Alpha Modus has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Alpha Modus	N/A	N/A	-610.34%

Summary

Alpha Modus beats Qualigen Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Datasea?

Datasea (NASDAQ:DTSS) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap technology companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Datasea had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Datasea and 0 mentions for Qualigen Therapeutics. Datasea's average media sentiment score of 0.92 beat Qualigen Therapeutics' score of 0.00 indicating that Datasea is being referred to more favorably in the media.

Company	Overall Sentiment
Datasea	Positive
Qualigen Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Datasea	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Datasea	N/A	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-202.16%

Datasea has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Datasea has higher revenue and earnings than Qualigen Therapeutics. Datasea is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Datasea	$40.70M	0.17	-$2.13M	-$0.32	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

82.1% of Datasea shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 50.7% of Datasea shares are held by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Datasea beats Qualigen Therapeutics on 9 of the 10 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Nvni Group?

Nvni Group (NASDAQ:NVNI) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap technology companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

In the previous week, Nvni Group's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nvni Group	Neutral
Qualigen Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nvni Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics has lower revenue, but higher earnings than Nvni Group. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Nvni Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nvni Group	$196.00M	0.05	-$20.22M	$0.40	2.25
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Company	Net Margins	Return on Equity	Return on Assets
Nvni Group	N/A	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-202.16%

Nvni Group has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

0.5% of Nvni Group shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 20.0% of Nvni Group shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Nvni Group beats Qualigen Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Next Technology?

Qualigen Therapeutics (NASDAQ:QLGN) and Next Technology (NASDAQ:NXTT) are both small-cap technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

Qualigen Therapeutics has a net margin of 0.00% compared to Next Technology's net margin of -2,355.97%. Qualigen Therapeutics' return on equity of 0.00% beat Next Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Next Technology	-2,355.97%	-60.08%	-53.71%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Next Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Next Technology had 3 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for Next Technology and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Next Technology'saverage media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Next Technology	Neutral

Next Technology has higher revenue and earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Next Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Next Technology	$11.61M	0.65	$143.16M	-$12.90 thousand	N/A

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 2.7% of Next Technology shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 52.2% of Next Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Next Technology has a beta of 5.98, suggesting that its share price is 498% more volatile than the broader market.

Summary

Next Technology beats Qualigen Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Qualigen Therapeutics compare to SeaChange International?

SeaChange International (NASDAQ:SEAC) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap technology companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Company	Net Margins	Return on Equity	Return on Assets
SeaChange International	N/A	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-202.16%

Qualigen Therapeutics has lower revenue, but higher earnings than SeaChange International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SeaChange International	$32.76M	0.25	-$11.40M	N/A	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SeaChange International	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.2% of Qualigen Therapeutics shares are owned by institutional investors. 3.9% of SeaChange International shares are owned by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, SeaChange International's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
SeaChange International	Neutral
Qualigen Therapeutics	Neutral

SeaChange International has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Summary

SeaChange International and Qualigen Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QLGN vs. The Competition

Export

Metric	Qualigen Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$2.09M	$16.24B	$31.92B	$13.26B
Dividend Yield	N/A	3.42%	2.75%	17.36%
P/E Ratio	-0.16	145.16	82.03	26.20
Price / Sales	N/A	1,281.22	585.60	91.08
Price / Cash	N/A	43.04	48.60	34.70
Price / Book	-0.30	8.88	8.22	6.40
Net Income	-$6.26M	$429.52M	$766.00M	$381.07M
7 Day Performance	-25.90%	1.46%	1.51%	-0.30%
1 Month Performance	73.39%	-1.27%	0.31%	-4.53%
1 Year Performance	-75.55%	0.71%	167.72%	1.62%

Qualigen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QLGN Qualigen Therapeutics	N/A	$1.23 +0.8%	N/A	-76.5%	$2.09M	N/A	N/A	50
AMOD Alpha Modus	2.6542 of 5 stars	$1.66 -12.6%	$60.00 +3,514.5%	-91.6%	$9.47M	$10K	N/A	9	News Coverage Gap Up
DTSS Datasea	1.0636 of 5 stars	$0.90 +0.2%	N/A	-66.0%	$9.40M	$40.70M	N/A	120	Gap Down
NVNI Nvni Group	1.3321 of 5 stars	$0.94 +0.8%	N/A	+187.3%	$9.33M	$35.23M	2.34	477	Gap Up
NXTT Next Technology	0.4274 of 5 stars	$5.70 -8.8%	N/A	-99.8%	$9.21M	$11.61M	N/A	28

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QLGN) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qualigen Therapeutics (QLGN) Competitors

QLGN vs. AMOD, DTSS, NVNI, NXTT, and SEAC

How does Qualigen Therapeutics compare to Alpha Modus?

Summary

How does Qualigen Therapeutics compare to Datasea?

Summary

How does Qualigen Therapeutics compare to Nvni Group?

Summary

How does Qualigen Therapeutics compare to Next Technology?

Summary

How does Qualigen Therapeutics compare to SeaChange International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qualigen Therapeutics (QLGN) Competitors

QLGN vs. AMOD, DTSS, NVNI, NXTT, and SEAC

How does Qualigen Therapeutics compare to Alpha Modus?

Which has preferable earnings & valuation, QLGN or AMOD?

Do insiders & institutionals have more ownership in QLGN or AMOD?

Does the media favor QLGN or AMOD?

Do analysts rate QLGN or AMOD?

Which has more volatility & risk, QLGN or AMOD?

Is QLGN or AMOD more profitable?

Summary

How does Qualigen Therapeutics compare to Datasea?

Does the media favor DTSS or QLGN?

Do analysts rate DTSS or QLGN?

Is DTSS or QLGN more profitable?

Which has more volatility and risk, DTSS or QLGN?

Which has higher valuation and earnings, DTSS or QLGN?

Do insiders and institutionals believe in DTSS or QLGN?

Summary

How does Qualigen Therapeutics compare to Nvni Group?

Does the media prefer NVNI or QLGN?

Do analysts recommend NVNI or QLGN?

Which has better valuation and earnings, NVNI or QLGN?

Is NVNI or QLGN more profitable?

Which has more volatility & risk, NVNI or QLGN?

Do institutionals and insiders believe in NVNI or QLGN?

Summary

How does Qualigen Therapeutics compare to Next Technology?

Is QLGN or NXTT more profitable?

Do analysts recommend QLGN or NXTT?

Does the media favor QLGN or NXTT?

Which has preferable earnings and valuation, QLGN or NXTT?

Do insiders & institutionals believe in QLGN or NXTT?

Which has more risk & volatility, QLGN or NXTT?

Summary

How does Qualigen Therapeutics compare to SeaChange International?

Is SEAC or QLGN more profitable?

Which has higher valuation & earnings, SEAC or QLGN?

Do analysts prefer SEAC or QLGN?

Do insiders and institutionals hold more shares of SEAC or QLGN?

Does the media refer more to SEAC or QLGN?

Which has more risk and volatility, SEAC or QLGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools